A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Inclusion Criteria:

1. Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal carcinoma.

2. Patients with the following histologic cell types are eligible: serous
adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,
undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial
adenocarcinoma, transitional cell carcinoma, malignant Brenner's tumor or
adenocarcinoma not otherwise specified.

3. Patient must have measurable disease as defined by RECIST 1.1.

4. Patients must have received treatment with a platinum-based chemotherapeutic regimen
for management of primary disease containing carboplatin, cisplatin or another
organoplatinum compound. This initial treatment may have included intraperitoneal
therapy, consolidation, non-cytotoxic agents or extended therapy administered after
surgical or non-surgical assessment.

Patients are allowed to receive, but are not required to receive, one additional
cytotoxic regimen for management of recurrent or persistent disease.

Patients are allowed to have received, but are not required to have received,
biologic/targeted therapy (e.g., bevacizumab and/or PARP inhibitor) as part of their
primary treatment regimen or for management of recurrent or persistent disease.

5. Patients must have platinum-resistant disease, defined as having a platinum-free
interval (PFI) of < 12 months after first- or second-line platinum-based
chemotherapy, or having disease progression while receiving second-line
platinum-based chemotherapy.

6. Patients must have adequate bone marrow, renal, hepatic, and neurologic functions as
defined by the following:

- Bone marrow function: absolute neutrophil count (ANC) ≥ 1,500/mm3. This ANC
cannot have been induced or supported by granulocyte colony stimulating factors.
Platelets ≥ 100,000/mm3. Hemoglobin ≥ 9 g/dL.

- Renal function: creatinine ≤ 1.5 x institutional upper limit normal (ULN).

- Hepatic function: bilirubin < 1.2 mg/dL, SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN
and alkaline phosphatase ≤ 2.5 x ULN.

7. Patients must have recovered from effects of recent surgery, radiotherapy or
chemotherapy:

- Patients should be free of active infection requiring parenteral antibiotics.

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration. Continuation of hormone replacement
therapy is permitted.

- Any other prior therapy directed at the malignant tumor, including chemotherapy,
biologic/targeted agents and immunologic agents, must be discontinued at least
three weeks prior to registration.

- Any prior radiation therapy must be completed at least four weeks prior to
registration.

8. Patients must have a GOG performance status of 0 or 1.

9. Patients of childbearing potential must have a negative pregnancy test prior to the
study entry and be practicing an effective form of contraception. If applicable,
patients must discontinue breastfeeding prior to study entry.

10. Patients must meet the entry requirements and undergo the baseline procedures.

11. Patients must have signed an IRB-approved informed consent form and authorization
permitting release of personal health information.

Exclusion Criteria:

1. Patients who have had treatment with VTX-2337, doxorubicin, PLD, or any other
anthracycline.

2. Patients who have received an investigational agent < 30 days prior to registration.

3. Patients who have received oral or parenteral corticosteroids < 2 weeks prior to
registration or who require ongoing systemic immunosuppressive therapy for any
reason.

4. Patients with active autoimmune disease. "Active" refers to any condition currently
requiring therapy. Examples of autoimmune disease include systemic lupus
erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid
arthritis.

5. Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, are excluded if there is any evidence of the other
malignancy being present within the last three years.

6. Patients who have received prior radiotherapy OTHER THAN for the treatment of
ovarian, fallopian tube or primary peritoneal cancer within the last three years are
excluded.

7. Patients who have received prior chemotherapy OTHER THAN for the treatment of
ovarian, fallopian tube or primary peritoneal cancer within the last three years are
excluded.

8. Patients with history or evidence upon physical examination of CNS disease, including
primary brain tumor, seizures not controlled with standard medical therapy, any brain
metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic
attack (TIA) or subarachnoid hemorrhage within six months of the first date of
treatment on this study.

9. Patients with clinically significant cardiovascular disease.

10. Patients who are pregnant or nursing.

11. Patients under the age of 18.

12. Patients with clinical symptoms or signs of gastrointestinal obstruction and/or who
require parenteral hydration or nutrition.